Table 7.

Factors associated with elevated FPG by gender.

	Q1	Q2	Q3	Q4
Men
GGT (U/L)	≤20	21–29	30–43	≥44
Cases/subjects at risk	210/1,178	280/1,213	393/1,167	488/1,206
OR (95% CI: lower–upper)	1.00	1.15 (0.92–1.44)	1.75 (1.41–2.19)	2.23 (1.77–2.80)
ALT (U/L)	≤19	20–27	28–38	≥39
Cases/subjects at risk	275/1,191	346/1,201	345/1,188	405/1,184
OR (95% CI: lower–upper)	1.00	1.04 (0.84–1.29)	0.95 (0.75–1.19)	1.10 (0.84–1.44)
AST (U/L)	≤24	25–30	31–36	≥37
Cases/subjects at risk	277/1,214	329/1,294	330/1,145	435/1,111
OR (95% CI: lower–upper)	1.00	1.08 (0.88­–1.33)	1.13 (0.91–1.40)	1.56 (1.25–1.95)
ALP (U/L)	≤52	53–61	62–71	≥72
Cases/subjects at risk	356/1,288	314/1,106	332/1,202	369/1,168
OR (95% CI: lower–upper)	1.00	0.95 (0.77–1.16)	0.92 (0.75–1.12)	0.95 (0.78–1.15)
Women
GGT (U/L)	≤13	14–17	18–22	≥23
Cases/subjects at risk	160/1,843	193/1,386	243/1,151	463/1,409
OR (95% CI: lower–upper)	1.00	1.46 (1.16–1.84)	1.90 (1.51–2.39)	2.38 (1.90–2.99)
ALT (U/L)	≤13	14–18	19–23	≥24
Cases/subjects at risk	147/1,480	210/1,624	251/1,248	451/1,437
OR (95% CI: lower–upper)	1.00	1.24 (0.95–1.62)	1.35 (1.02–1.79)	1.55 (1.15–2.09)
AST (U/L)	≤22	23–26	27–31	≥32
Cases/subjects at risk	154/1,451	231/1,494	250/1,434	424/1,410
OR (95% CI: lower–upper)	1.00	1.32 (1.05–1.68)	1.17 (0.93–1.49)	1.86 (1.48–2.35)
ALP (U/L)	≤42	43–51	52–63	≥64
Cases/subjects at risk	159/1,556	181/1,352	316/1,519	403/1,362
OR (95% CI: lower–upper)	1.00	1.25 (0.95–1.65)	1.78 (1.38–2.30)	1.85 (1.41–2.42)